Morphine Sulfate Injection shortage
Morphine Sulfate Injection is currently listed in shortage by the FDA. The FDA lists 24 affected products. The reported reason: Other; Demand increase for the drug; Discontinuation of the manufacture of the drug. This page was last refreshed from FDA data on Oct 2, 2026.
Morphine sulfate injection is currently in shortage, with four strengths — 8 mg/mL, 50 mg/mL, 5 mg/mL, and 10 mg/mL syringes — having no available source right now. Other strengths remain listed by makers not reporting a shortage, including Hospira, Hikma, Fresenius Kabi, and Civica.
Don’t stop or change your therapy on your own — ask your pharmacist about other manufacturers (see options) and your prescriber about a long-term plan.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Morphine Sulfate Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Sep 22, 2026Currently in shortage24 of 24 products affected.
-
Sep 18, 2026FDA refreshed this shortage record7 products updated.
-
Sep 16, 2026FDA refreshed this shortage record1 product updated.
-
Sep 15, 2026FDA refreshed this shortage record8 products updated.
-
Dec 6, 2018More presentations reported1 more product added to the shortage.
-
Nov 3, 2017More presentations reported7 more products added to the shortage.
-
Oct 31, 2017First reported to the FDA16 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Amphastar Pharmaceuticals, Inc. 📞 800-423-4136 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Morphine Sulfate, Injection, 1 mg/1 mL (NDC 76329-1912-1) | — | Available | — | — |
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 6 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Morphine Sulfate, Injection, 2 mg/1 mL (NDC 63323-452-01) | — | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other |
| Current | Morphine Sulfate, Injection, 4 mg/1 mL (NDC 76045-005-11) | — | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other |
| Current | Morphine Sulfate, Injection, 5 mg/1 mL (NDC 63323-455-01) | — | Unavailable | Estimated recovery: TBD | Demand increase for the drug |
| Current | Morphine Sulfate, Injection, 10 mg/1 mL (NDC 63323-451-01) | — | Available | Check wholesalers for inventory | — |
| Current | Morphine Sulfate, Injection, 4 mg/1 mL (NDC 63323-454-01) | — | Unavailable | Next release October 2026. Check wholesalers for inventory. | Other |
| Current | Morphine Sulfate, Injection, 2 mg/1 mL (NDC 76045-004-11) | — | Unavailable | Next release September 2026. Check wholesalers for inventory. | Other |
Manufacturer: Hikma Pharmaceuticals USA, Inc. 📞 800-631-2174 7 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Duramorph, Injection, 1 mg/1 mL (NDC 0641-6019-10) | — | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — |
| Current | Infumorph 500 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 25 mg/1 mL (NDC 0641-6040-01) | — | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — |
| Current | Infumorph 200 (Preservative-Free Morphine Sulfate Sterile Solution), Injection, 10 mg/1 mL (NDC 0641-6039-01) | — | Unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug |
| Current | Morphine Sulfate, Injection, 8 mg/1 mL (NDC 0641-6126-25) | — | unavailable | Additional lots will be available in the October 2026 timeframe. Product will be made available as it is released. | Demand increase for the drug |
| Current | Duramorph, Injection, .5 mg/1 mL (NDC 0641-6020-10) | — | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — |
| Current | Morphine Sulfate, Injection, 10 mg/1 mL (NDC 0641-6127-25) | — | Unavailable | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | Demand increase for the drug |
| Current | Morphine Sulfate, Injection, 4 mg/1 mL (NDC 0641-6125-25) | — | Available | Additional lots are scheduled to be manufactured. Product will be made available as it is released. | — |
Manufacturer: Hospira, Inc., a Pfizer Company 📞 844-646-4398 8 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Morphine Sulfate, Injection, 2 mg/1 mL Syringes (NDC 0409-1890-01) | — | Available | — | — |
| Current | Morphine Sulfate, Injection, 2 mg/1 mL (NDC 0409-1890-23) | — | Limited Availability | Limited Supply Available. Next Delivery: November 2026; Estimated Recovery: December 2026; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-1896-20) | — | Unavailable | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Morphine Sulfate, Injection, 10 mg/10 mL (1 mg/mL) (NDC 0409-3815-12) | — | Available | — | — |
| Current | Morphine Sulfate, Injection, 5 mg/10 mL (0.5 mg/mL) (NDC 0409-3814-12) | — | Available | — | — |
| Current | Morphine Sulfate, Injection, 50 mg/1 mL (NDC 0409-2022-01) | — | Unavailable | Next Delivery: January 2027; Estimated Recovery: March 2027; Shortage per Manufacturer: Manufacturing Delay | Other |
| Current | Morphine Sulfate, Injection, 10 mg/1 mL Syringes (NDC 0409-1893-01) | — | Unavailable | Discontinuation of the manufacture of the drug | Discontinuation of the manufacture of the drug |
| Current | Morphine Sulfate, Injection, 4 mg/1 mL Syringes (NDC 0409-1891-01) | — | Available | — | — |
Manufacturer: Piramal Critical Care Inc. 📞 800-414-1901 2 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| Current | Mitigo, Injection, 500 mg/20 mL (NDC 66794-162-02) | — | Available | — | — |
| Current | Mitigo, Injection, 200 mg/20 mL (NDC 66794-160-02) | — | Available | — | — |
These rows are manufacturer reports to the FDA for Morphine Sulfate Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Morphine Sulfate Injection? options further down this page.
Why is Morphine Sulfate Injection in shortage?
There are a few different things going on with morphine sulfate injection right now, depending on the manufacturer and the specific strength. For Fresenius Kabi, several strengths are currently unavailable — the 2 mg/mL and 4 mg/mL vials are expected back around September–October 2026, while the 5 mg/mL vials have no firm return date yet due to higher-than-usual demand. Their 10 mg/mL vials are still available. For Hospira (Pfizer), factory hold-ups (manufacturing delays) are affecting the 2 mg/mL vials (some limited supply exists, with more expected by November–December 2026) and the 50 mg/mL vials (next delivery expected January 2027, recovery estimated March 2027). Hospira has also permanently stopped making their 10 mg/mL syringes — that specific product will not be coming back from them. Their 2 mg/mL syringes, 4 mg/mL syringes, and 10 mg/10 mL vials remain available.
For Hikma, increased demand is behind shortages of the 8 mg/mL, 10 mg/mL, and Infumorph 200 (10 mg/mL preservative-free) products, with additional lots expected around October 2026. Hikma's 4 mg/mL vials, Infumorph 500 (25 mg/mL), and Duramorph products are still available from them.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Morphine Sulfate Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Morphine Sulfate Injection?
Morphine Sulfate Injection is currently on the FDA shortage list. Most strengths still have a supplier, so if you or the person you care for uses one of those, there is a good chance your pharmacy can locate it.
Four strengths currently have no available source: 8 mg/1 mL, 50 mg/1 mL, 5 mg/1 mL, and the 10 mg/1 mL Syringes. The other twelve strengths — including 4 mg/1 mL, 2 mg/1 mL, 1 mg/1 mL, 10 mg/10 mL, 25 mg/1 mL, 200 mg/20 mL, 500 mg/20 mL, and the 2 mg and 4 mg Syringes — still show an available source.
All five manufacturers on this record are still reporting some supply. The reported reasons include increased demand, a manufacturing/other issue, and one product being discontinued. Some strengths have expected release dates in late 2026; the 10 mg/1 mL Syringes are being discontinued, which may make that specific item unavailable going forward.
Here is what I suggest:
- Do not stop, skip, or change any doses on your own.
- If your strength still has supply, ask your pharmacy to order it — they can check wholesalers and other makers.
- The same medicine is made by several companies, so your pharmacy may be able to source another maker's version, though it may not be in local stock.
- If your exact strength is discontinued or cannot be found, ask your prescriber or pharmacist about options.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national data and may not match local stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
- This is a controlled substance. Transfers between pharmacies and switching strengths have extra federal/state rules — ask the pharmacy before you assume a transfer is possible.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Morphine Sulfate Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Morphine Sulfate Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Morphine Sulfate | MORPHINE SULFATE 4 mg/mL | Injection, Solution · Intravenous | Hospira, Inc. | 00409-1891-23 |
| Morphine Sulfate | MORPHINE SULFATE 10 mg/mL | Injection, Solution · Intravenous | Hospira, Inc. | 00409-1893-23 |
| Morphine Sulfate | MORPHINE SULFATE 2 mg/mL | Injection · Intravenous | Hikma Pharmaceuticals USA Inc. | 00641-6191-10 |
| Morphine Sulfate | MORPHINE SULFATE 4 mg/mL | Injection · Intravenous | Hikma Pharmaceuticals USA Inc. | 00641-6192-10 |
| Morphine Sulfate | MORPHINE SULFATE 8 mg/mL | Injection, Solution · Intramuscular, Intravenous | Fresenius Kabi USA, LLC | 63323-0458-01 |
| Morphine Sulfate | MORPHINE SULFATE 4 mg/mL | Injection · Intravenous | Civica, Inc. | 72572-0440-25 |
| Morphine Sulfate | MORPHINE SULFATE 8 mg/mL | Injection, Solution · Intramuscular, Intravenous | Fresenius Kabi, USA LLC | 76045-0007-10 |
| Morphine Sulfate | MORPHINE SULFATE 10 mg/mL | Injection, Solution · Intramuscular, Intravenous | Fresenius Kabi, USA LLC | 76045-0008-10 |
Alternative dosage forms of Morphine Sulfate
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 7 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Morphine Sulfate 1 mg/30mL | International | 1 vial | — | — | FDA listed |
| Morphine Sulfate 2 mg/mL | Fresenius | 25 vials | — | — | FDA listed |
| Morphine Sulfate 2 mg/mL | Fresenius | 1 syringe | — | — | Discontinued |
| Morphine Sulfate 4 mg/mL | Hospira, | 10 syringes | — | AP | Discontinued |
| Morphine Sulfate 4 mg/mL | Hikma | 10 syringes | — | AP | FDA listed |
| Morphine Sulfate 4 mg/mL | Fresenius | 10 syringes | — | — | FDA listed |
| Morphine Sulfate 4 mg/mL | Fresenius | 25 vials | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Morphine Sulfate Injection — that fall in the same broad treatment class (opioid analgesics) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other analgesia/addiction shortages
Morphine Sulfate Injection shortage FAQs
Is Morphine Sulfate Injection in shortage?
Why is Morphine Sulfate Injection in shortage?
Which products are affected?
When will Morphine Sulfate Injection be available again?
Can I still get Morphine Sulfate somewhere?
What should I do if I take Morphine Sulfate Injection?
Still have a question about the Morphine Sulfate Injection shortage?
Ask a pharmacist about this shortage →View Morphine Sulfate Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.